logo
At China's robot school, machines learn like humans, teacher uses VR headset

At China's robot school, machines learn like humans, teacher uses VR headset

Yahoo2 days ago
A specialized training facility in China has taken on its first cohort of 'robot students'. Located in Hefei—capital of the eastern province of Anhui—this new 'robot school' is being used to teach robots technical skills, such as holding and using tools.
The robot students are taught fine motor skills by a human teacher a wearing virtual reality (VR) headset and holding motion-sensing controllers. According to reports, one student robot arm is learning how to pick up a wrench and tighten a screw using this method.
The school, technically referred to as an embodied intelligent robot training environment, is essentially a high-tech training ground for robots, situated on a simulated factory floor.
"Our aim is to train robots to generalize from one example to others, so that they can perform reliably no matter the setting—and that only comes through real-world exposure," said Ji Chao, founder of a robotics company based in Hefei and a developer involved with the training facility.
"The service-based support model allows robot developers to purchase professional services regarding computing power, training scenarios, and data acquisition for algorithm iteration at reasonable costs, thus creating a virtuous circle," observed Sun Dandan, an executive at the robotics division of China's International Advanced Technology Application Promotion Center, which is independently running the program.
At present, robots from various Chinese companies are being taught how to function in specific work scenarios. These include, but not limited to, logistics and warehouse handling, picking and sorting parts, home assistance, and providing retail and tour guide customer service.
The training curriculum is pretty intense at the school, with human trainers inputting 200 action sequences per day per robot. These actions are collected as real-world physical data (not just code or simulations).
https://www.youtube.com/watch?v=-nTHdVlnnlU&pp=ygUYdGVhY2hpbmcgcm9ib3RzIHVzaW5nIHZy
Each robot uses this data to train machine learning models, which will eventually enable it to perform the task autonomously. The idea is not just memorizing a motion (e.g., turning a screw) but understanding how to adapt on the fly, such as recognizing different types of screws.
Real-world training like this exposes robots to unpredictable scenarios such as uneven surfaces, dropped tools, and unusual objects, which simulations often struggle to replicate well. The training is believed to help enhance the robots' ability to generalize across environments, making them more effective in real-world applications.
The school is the first public robot training platform of its kind in China. It offers shared infrastructure like computing power, datasets, and realistic environments, which is rare and expensive for smaller companies to build alone.
The initiative also supports various business models, and companies can co-run, operate independently, or purchase training and data services. The program helps bridge the 'gap', or the disparity between simulated training and actual performance in the real world.
It also promotes collaboration, standardization, and scalability in China's growing robotics sector. The ultimate goal is to expedite the development of more capable, general-purpose autonomous robots.
To sum up, the robot school is something of a real-world machine learning lab for robots which would enable them to work more independently in factories, warehouses, homes, or stores eventually.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asian Penny Stocks To Watch With Market Caps At Least US$200M
Asian Penny Stocks To Watch With Market Caps At Least US$200M

Yahoo

timean hour ago

  • Yahoo

Asian Penny Stocks To Watch With Market Caps At Least US$200M

As global markets continue to navigate a complex landscape, Asian stocks remain a focal point for investors seeking opportunities in diverse economies. Penny stocks, often overlooked due to their vintage nomenclature, still represent an intriguing segment for those interested in smaller or newer companies. By focusing on financial robustness and growth potential, these stocks can offer unexpected value and stability amidst broader market movements. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.28 HK$807.62M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$2.09 HK$3.61B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.22 HK$1.85B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.42 SGD170.22M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.11 HK$1.85B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.38 THB2.63B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.19 SGD8.62B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.21 SGD42.46M ★★★★★★ BRC Asia (SGX:BEC) SGD3.17 SGD869.69M ★★★★★★ United Energy Group (SEHK:467) HK$0.52 HK$13.44B ★★★★★★ Click here to see the full list of 991 stocks from our Asian Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Inkeverse Group Limited is an investment holding company that operates mobile live streaming platforms in the People's Republic of China, with a market cap of HK$2.56 billion. Operations: The company generates revenue primarily from its Live Streaming Business, which amounted to CN¥6.85 billion. Market Cap: HK$2.56B Inkeverse Group, with a market cap of HK$2.56 billion, primarily generates revenue from its Live Streaming Business amounting to CN¥6.85 billion. Despite being debt-free and having strong short-term assets (CN¥4 billion) exceeding liabilities, the company faces challenges with negative earnings growth (-53.4%) and reduced profit margins (2.6% from 5.6%). A significant one-off loss of CN¥99.7 million impacted recent financials, highlighting volatility in performance despite stable weekly volatility at 8%. The experienced board and management team offer some stability as the company trades below estimated fair value by 24.2%. Click here and access our complete financial health analysis report to understand the dynamics of Inkeverse Group. Evaluate Inkeverse Group's historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Low Keng Huat (Singapore) Limited is an investment holding company involved in property development, hotel operations, and investments across Singapore, Australia, and Malaysia with a market cap of SGD280.75 million. Operations: The company's revenue is primarily derived from property development at SGD415.78 million, supplemented by hotel operations generating SGD50.08 million and investments, including construction, contributing SGD66.71 million. Market Cap: SGD280.75M Low Keng Huat (Singapore) Limited, with a market cap of SGD280.75 million, derives significant revenue from property development (SGD415.78 million), hotel operations (SGD50.08 million), and investments including construction (SGD66.71 million). The company recently became profitable, although earnings have declined by 50.5% annually over the past five years. Short-term assets of SGD409 million comfortably cover both short and long-term liabilities, yet the net debt to equity ratio remains high at 62.1%. Despite stable weekly volatility at 6%, interest coverage is weak at 1.3x EBIT, and dividend payments are not well supported by earnings. Get an in-depth perspective on Low Keng Huat (Singapore)'s performance by reading our balance sheet health report here. Gain insights into Low Keng Huat (Singapore)'s historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Xiamen Hexing Packaging Printing Co., Ltd. operates in the packaging and printing industry, with a market cap of CN¥4.19 billion. Operations: The company generates revenue of CN¥11.23 billion from its packaging manufacturing industry segment. Market Cap: CN¥4.19B Xiamen Hexing Packaging Printing Co., Ltd. demonstrates a stable financial position with short-term assets of CN¥4.4 billion exceeding both its short and long-term liabilities, reflecting solid liquidity. The company's net debt to equity ratio at 16.6% is satisfactory, and its interest payments are well covered by EBIT at 3.5x coverage, indicating manageable leverage levels. While earnings growth over the past year outpaced the industry average, profitability remains modest with a net profit margin of 1%. Recent activities include a share buyback program worth up to CN¥100 million and a cash dividend increase, suggesting shareholder-friendly initiatives despite fluctuating revenue figures. Take a closer look at Xiamen Hexing Packaging Printing's potential here in our financial health report. Examine Xiamen Hexing Packaging Printing's earnings growth report to understand how analysts expect it to perform. Discover the full array of 991 Asian Penny Stocks right here. Ready For A Different Approach? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3700 SGX:F1E and SZSE:002228. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Samsung Expects Quarterly Operating Profit to Drop 56%
Samsung Expects Quarterly Operating Profit to Drop 56%

Wall Street Journal

timean hour ago

  • Wall Street Journal

Samsung Expects Quarterly Operating Profit to Drop 56%

Samsung 005930 -2.53%decrease; red down pointing triangle Electronics expects its operating profit for the second quarter to more than halve from a year earlier amid a weak recovery in its semiconductor segment, missing market expectations. The South Korean technology giant attributed its downbeat earnings guidance partly to its one-off cost to recognize inventory value losses stemming from U.S. curbs on advanced-chip exports to China.

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

Yahoo

timean hour ago

  • Yahoo

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma' or the 'Company'), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company's Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company's Chairman & Chief Executive Officer. Dr. Yang said, 'I am excited to welcome Veet and Eric to our senior management team. As an innovative biopharmaceutical company dual listed on the Hong Kong Stock Exchange and Nasdaq, Ascentage Pharma is entering a phase of notable growth. The addition of these seasoned executives will help accelerate the implementation of our global strategy of becoming a leading, fully integrated global biopharmaceutical company.' Dr. Misra brings a rare combination of deep scientific background in biology and significant experience in U.S. capital markets in the biopharmaceutical sector. 'I am confident that Veet's unique blend of scientific acumen and capital markets expertise can help us garner stronger traction in the global capital markets and strengthen our operations,' added Dr. Yang. Mr. Huang brings rich expertise in the global pharmaceutical industry and a wealth of experience in corporate management. 'This makes Eric a great match for Ascentage Pharma's long-term growth needs. His experience will help drive excellence in Ascentage Pharma's corporate operations as the Company continues to make headway in expanding globally,' said Dr. Yang. Dr. Misra commented, 'I am thrilled to join Ascentage Pharma as its Chief Financial Officer. Ascentage Pharma is a global leader in apoptosis-targeted therapies. Its dual listing in Hong Kong and the U.S. reflects strong recognition of the Company in these two premier markets. I look forward to working with my colleagues to accelerate the global development of the Company's innovative pipeline and create sustained value for patients and shareholders.' Mr. Huang said, 'It is my great honor to join Ascentage Pharma, a company that has established growing global competitiveness in the field of hematologic malignancies. The strategic partnership with Takeda and the dual listing in Hong Kong and the U.S. have created a sound foundation for global expansion. I look forward to working closely with the Company's management team to further improve operations and efficiently integrate the Company's existing resources to accelerate the global development and commercialization of its core assets, ultimately bringing more novel therapeutics to patients in need.' Dr. Misra has more than 20 years of experience in investment banking. Prior to joining Ascentage Pharma, he was a Managing Director in the Healthcare Investment Banking group at Cantor Fitzgerald where he covered the biopharmaceutical sector. Before that, he worked in the life sciences investment banking groups at Houlihan Lokey and RBC Capital Markets. Over the course of his banking career, Dr. Misra advised on deals spanning equity, equity-linked, debt, and debt restructuring, as well as buy-side/sell-side M&A and corporate strategy, primarily focusing on the biotechnology sector. Dr. Misra earned a Ph.D. in Molecular Biology, with a focus on the oncology field, from the University of Toronto and an MBA in Finance & Strategy from the Schulich School of Business in Toronto. Mr. Huang has served in various managerial positions at multinational companies for more than 20 years and possesses extensive experience in driving continuous financial performance improvement, business/operational excellence, and global operations. Prior to joining Ascentage Pharma, Mr. Huang served as the Chief Financial Officer for Greater China and Asia-Pacific at Beigene, where he also led Global Technical Operations Finance and Global Commercial Finance, and implemented comprehensive financial planning management and optimized globally-based resource allocation leading to sustained financial improvements. Before that, Mr. Huang was at Novartis, where he served as the head of finance for multiple countries and regions. Mr. Huang received an MBA in Finance from Dowling Business School. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor Relations:Hogan Wan, Head of IR and StrategyAscentage 512 85557777 Stephanie CarringtonICR (646) 277-1282 Media Relations:Sean LeousICR (646) 866-4012

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store